Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* -- Results Q4 2022 -- -0.79 --
02/24/2023* 11:30 EST Earnings Call Q4 2022 -- -- --
11/09/2022 -- Results Q3 2022 -0.16 -0.53 69.67%
11/09/2022 11:30 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.56 -0.47 -20.10%
08/09/2022 11:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.27 -0.52 47.12%
05/04/2022 11:30 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2022
Beat/Miss Upgrade
Return Since -6.36%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
0.31%
-22.77%
5.16%
7.48%
11.75%
-6.41%
-46.18%
32.50%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
15.88%
-20.92%
7.64%
-4.51%
-0.70%
3.71%
0.75%
19.48%
66.00%
45.78%
148.8%
-26.02%
-9.43%
116.2%
-24.31%
26.16%
--
--
--
--
-7.42%
-45.46%
-67.76%
-58.52%
--
--
--
--
--
113.0%
56.35%
-34.06%
As of December 02, 2022.

Profile

Edit
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
EAGB.NO 880688.0 USD 5.22%
ARKG 115.08M USD 5.11%
SBIO 3.692M USD 3.16%
LMPFX 92.29M USD 2.19%
FXH 26.68M USD 1.66%
TBGVX 80.48M USD 1.51%
FBIOX 55.14M USD 1.08%
FGKFX 83.48M USD 0.86%
FCGSX 91.58M USD 0.84%
XT 25.62M USD 0.82%
FGCKX 314.18M USD 0.80%
ISCG 1.340M USD 0.34%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter IONS Tweets